CervoMed Surges 57% During Trading After US Patent Approval for DLB Drug
CervoMed(CRVO.US) 盘中涨57.48%，现报6.0美元。
公司获得美国专利商标局批准一项专利，涵盖 neflamapimod 在纯路易体痴呆患者中的使用，保护期延长至 2042 年。该专利针对无显著阿尔茨海默病样 tau 病理的 DLB 患者。neflamapimod 已完成 2b 期临床试验，3 期试验时间取决于能否获得合作伙伴关系或额外融资。
Source: US Stock Market Update The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments